Abstract
Introduction The aim of this study was to determine pathological variants of childhood focal segmental glomerulosclerosis and assess efficacy of prednisolone + methylprednisolone + cyclosporin A treatment. Materials and methods This retrospective cohort study included 134 native Kazakh children (3 months–17 years) with nephrotic syndrome hospitalised in the Nephrology Department of the Republic Children’s Clinical Hospital from 2004 to 2011. Kidney biopsy and pathological investigations were performed in 38 nephrotic syndrome patients with proven steroid resistance. Results Focal segmental glomerulosclerosis was confirmed in 38 (28.4%) patients (treatment group). The main focal segmental glomerulosclerosis variants were glomerular tip lesions and not otherwise specified types. Historical (did not undergo kidney biopsy) controls were treated with cyclosporin A or alkylating agents. Prednisolone + methylprednisolone + cyclosporin A immunosuppressive therapy was highly effective, allowing complete remission in 88.9% patients with minimum side effects. Patients with the not otherwise specified variant (NPHS2 and WT1 mutations) did not achieve remission. Combination cyclosporin A treatment was significantly more effective than alkylating agent treatment in steroid-resistant nephrotic syndrome patients without genetic mutations. Conclusion Tip lesions are predominant in childhood steroid-resistant nephrotic syndrome. Prednisolone + methylprednisolone + cyclosporin A therapy is safe and effective for childhood focal segmental glomerulosclerosis. Establishing a podocyte mutation profile is important to predict treatment outcome.
Highlights
The aim of this study was to determine pathological variants of childhood focal segmental glomerulosclerosis and assess efficacy of prednisolone + methylprednisolone + cyclosporin A treatment
This study aimed to determine the pathological variants of childhood focal segmental glomerulosclerosis (FSGS) and test the safety and efficacy of combination immunosuppressive therapy comprising prednisolone (Pred) + methylprednisolone (MP) + cyclosporine A (CsA) in children diagnosed with FSGS and investigate the impact of pathological childhood FSGS variants associated with genetic mutations in podocytes on treatment outcome
The diagnosis of FSGS was confirmed in 38 children (16 boys and 22 girls; treatment group) with a mean age of 10.9 years (1.4–17 years; Table 1)
Summary
The aim of this study was to determine pathological variants of childhood focal segmental glomerulosclerosis and assess efficacy of prednisolone + methylprednisolone + cyclosporin A treatment. Materials and methods This retrospective cohort study included 134 native Kazakh children (3 months–17 years) with nephrotic syndrome hospitalised in the Nephrology Department of the Republic Children’s Clinical Hospital from 2004 to 2011. The disease is routinely managed by steroid therapy[1]. These patients may develop focal segmental glomerulosclerosis (FSGS), the major cause of childhood steroid-resistant nephrotic syndrome (SRNS). Early diagnosis of FSGS is essential to provide treatment alternatives and delay progression to end-stage renal disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
